Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY – Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,000 shares, a decrease of 50.0% from the February 13th total of 2,000 shares. Based on an average daily trading volume, of 600 shares, the days-to-cover ratio is currently 1.7 days.
Hikma Pharmaceuticals Trading Up 0.7 %
Shares of Hikma Pharmaceuticals stock traded up $0.39 during trading on Friday, hitting $52.79. The stock had a trading volume of 2,777 shares, compared to its average volume of 922. The business has a fifty day moving average of $54.73 and a two-hundred day moving average of $51.64. Hikma Pharmaceuticals has a fifty-two week low of $46.16 and a fifty-two week high of $59.26.
Hikma Pharmaceuticals Increases Dividend
The company also recently disclosed a dividend, which will be paid on Monday, May 12th. Stockholders of record on Friday, March 21st will be issued a $0.94 dividend. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.62. The ex-dividend date of this dividend is Friday, March 21st. Hikma Pharmaceuticals’s dividend payout ratio is 10.34%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- Following Congress Stock Trades
- How to Build the Ultimate Everything ETF Portfolio
- Business Services Stocks Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Quiet Period Expirations Explained
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.